Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase ; volume:12 ; number:3 ; year:2019 ; pages:913-917
Case reports in oncology ; 12, Heft 3 (2019), 913-917
- Urheber
-
Obeidat, Khaldun
Alsaud, Arwa
Ashour, Amr
Azrieh, Bahjat
Abu-Tineh, Mohammad
Mohamed, Shehab Fareed
Yassin, Mohamed A.
- DOI
-
10.1159/000504937
- URN
-
urn:nbn:de:101:1-2020011600185373789355
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Obeidat, Khaldun
- Alsaud, Arwa
- Ashour, Amr
- Azrieh, Bahjat
- Abu-Tineh, Mohammad
- Mohamed, Shehab Fareed
- Yassin, Mohamed A.
Ähnliche Objekte (12)
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia